How can Medicaid pay for the pricey new generation of hepatitis C drugs? Insurers want to know. And they're now asking state health agencies to pitch in, Reuters reports.
Martin's tenure has seen the company build blockbuster revenue from its HIV franchise while creating a new standard of care in the hepatitis C arena.
San Diego startup CURx has paid an undisclosed sum to license an antiobitic developed by Gilead, planning to launch a Phase III trial on the drug to treat lung infections in cystic fibrosis patients.
According to the latest survey from PatientView, in the healthcare industry, multinational pharma companies rank next to last, reputation-wise. Biotech companies come in just above that. Since 2011, pharma's reputation, already not so hot, has slipped even further.
As soon as Gilead Sciences named a price for its highly anticipated hep C drug Sovaldi, activists pounced--and payers showed some nervousness about laying out cash for another high-dollar treatment. Not to worry, Chief Operating Officer John Milligan says. Payers understand the big picture.
Gilead Sciences is starting to make some noise about Sovaldi's prospects: On Tuesday, CEO John Milligan told Reuters he still won't make a definitive sales projection about the drug, but he doesn't disagree with analysts' estimates.
In an interview with Bloomberg, COO John Milligan says the big biotech outfit--which is expected to generate megablockbuster revenue from the newly approved Sovaldi for hep C--is pondering a head-to-head study to determine whether Letairis is better or worse than Actelion's recently approved lung drug Opsumit.
Right on schedule, Gilead Sciences has submitted its combination hepatitis C treatment for FDA approval, inching toward the era of interferon-free treatment and widening its lead on rival AbbVie.
All the buzz about Gilead Sciences lately has been about hepatitis C. And no wonder: It has Sovaldi on its hands, a brand-new, breakthrough treatment expected to barrel past the blockbuster barrier almost immediately--and hit up to $7 billion in sales this year.
Indian drugmakers have a shot at bringing Gilead Sciences' hot new hepatitis C drug to their country. The California-based company is in talks with "a handful" of Indian pharmas to take Sovaldi to that country and other developing nations at a fraction of the U.S. price.